NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Update

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 40,100 shares, a decline of 96.8% from the September 15th total of 1,250,000 shares. Approximately 5.3% of the company’s stock are short sold. Based on an average daily volume of 72,600 shares, the short-interest ratio is currently 0.6 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NLS Pharmaceutics stock. Armistice Capital LLC grew its holdings in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) by 6.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,311,000 shares of the company’s stock after purchasing an additional 139,000 shares during the quarter. Armistice Capital LLC owned about 19.62% of NLS Pharmaceutics worth $501,000 as of its most recent filing with the SEC.

NLS Pharmaceutics Trading Up 4.7 %

Shares of NLS Pharmaceutics stock traded up $0.20 on Friday, hitting $4.45. 35,889 shares of the company traded hands, compared to its average volume of 106,292. NLS Pharmaceutics has a 12-month low of $4.08 and a 12-month high of $40.60. The company has a 50-day moving average price of $1.12 and a 200 day moving average price of $0.50.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).